KITS Eyecare (KITS) rebounded 9% on a $4.5M sales week, the highest in the company’s history and up 27% Y/Y - above the 25% growth management pre-released for Q3…

… which led to a >20% drawdown over the following month. Should the release be indicative of what’s to come in Q4, it would represent stabilization around mid-20s top-line growth and likely put a pause on multiple compression…

… with the help of a $2.4M buy from the CEO last week.